Source link : https://www.newshealth.biz/health-news/remarkable-weight-loss-with-novel-oral-combo-in-phase-1/
MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to phase 1, first-in-human study data presented at the European Association for the Study of Diabetes (EASD) 2024 annual meeting. Body weight loss was “remarkable for an orally delivered biologic,” […]
Author : News Health
Publish date : 2024-09-12 16:28:21
Copyright for syndicated content belongs to the linked Source.